Japanese companies agree to raise wages 5.58%    Asian shares hit two-year highs on China property measures    Gold soars to all-time high on rate cut bets    Government committed to facilitate easy financing for private sector: Finance Minister    Egyptian, Chinese transport officials discuss bilateral cooperation    Health Ministry adopts rapid measures to implement comprehensive health insurance: Abdel Ghaffar    Rafah crossing closure: Over 11k injured await vital treatment amidst humanitarian crisis in Gaza    Nouran Gohar, Diego Elias win at CIB World Squash Championship    Coppola's 'Megalopolis': A 40-Year Dream Unveiled at Cannes    World Bank assesses Cairo's major waste management project    Russian refinery halts operations amid attacks    Partnership between HDB, Baheya Foundation: Commitment to empowering women    NBE, CIB receive awards at EBRD Annual Meetings    Venezuela's Maduro imposes 9% tax for pensions    Health Minister emphasises state's commitment to developing nursing sector    20 Israeli soldiers killed in resistance operations: Hamas spokesperson    Sudan aid talks stall as army, SPLM-N clash over scope    Microsoft eyes relocation for China-based AI staff    K-Movement Culture Week: Decade of Korean cultural exchange in Egypt celebrated with dance, music, and art    Empower Her Art Forum 2024: Bridging creative minds at National Museum of Egyptian Civilization    Niger restricts Benin's cargo transport through togo amidst tensions    Egyptian consortium nears completion of Tanzania's Julius Nyerere hydropower project    Sweilam highlights Egypt's water needs, cooperation efforts during Baghdad Conference    AstraZeneca injects $50m in Egypt over four years    Egypt, AstraZeneca sign liver cancer MoU    Swiss freeze on Russian assets dwindles to $6.36b in '23    Prime Minister Madbouly reviews cooperation with South Sudan    Egypt retains top spot in CFA's MENA Research Challenge    Egyptian public, private sectors off on Apr 25 marking Sinai Liberation    Debt swaps could unlock $100b for climate action    Amal Al Ghad Magazine congratulates President Sisi on new office term    Financial literacy becomes extremely important – EGX official    Euro area annual inflation up to 2.9% – Eurostat    BYD، Brazil's Sigma Lithium JV likely    UNESCO celebrates World Arabic Language Day    Motaz Azaiza mural in Manchester tribute to Palestinian journalists    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Moderna receives $483 million in U.S. federal funding to speed up coronavirus vaccine development
Published in Amwal Al Ghad on 18 - 04 - 2020

Drug developer Moderna announced on Friday that it received as much as $483 million in U.S. federal funding to speed up the development of its potential coronavirus vaccine.
Moderna chief executive Stephane Bancel told CNBC that the funding is particularly critical in supporting manufacturing efforts.
"Instead of waiting for the data and then scaling up with manufacturing process … we can make as many doses as we can. We are doing both in parallel," Bancel said.
The company is planning to hire up to 150 people to support the scale-up efforts, he added.
Bancel said the company "couldn't have done this" without the funding commitment from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services.
The experimental vaccine is being tested in an early-stage trial run by the U.S. National Institutes of Health. Moderna expects to start mid-stage trial in the second quarter.
Based on the data from these studies and discussions with regulators, the company said a late-stage study could start as soon as autumn of 2020.


Clic here to read the story from its source.